Dopamine agonists and risk of lung cancer in patients with restless legs syndrome.
RLS
dopamine agonists
epidemiology
lung cancer
time-varying exposure
Journal
Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
revised:
20
01
2023
received:
23
08
2022
accepted:
28
01
2023
medline:
12
6
2023
pubmed:
11
2
2023
entrez:
10
2
2023
Statut:
ppublish
Résumé
To examine the association between long-term use of dopamine agonists (DAs) and the risk of lung cancer in patients with restless legs syndrome (RLS). We conducted a retrospective cohort study using Optum Clinformatics® database. We included adults ≥40 years diagnosed with RLS during the study period (1/2006-12/2016). Follow-up started with the first RLS diagnosis and ended on the earliest of: incident diagnosis of lung cancer, end of enrollment in the database or end of the study period. The exposure of interest was cumulative duration of DAs use, measured in a time-varying manner. We constructed a multivariable Cox regression model to estimate HRs and 95% CIs for the association between lung cancer and cumulative durations of DA use, adjusting for potential confounding variables. We identified 295 042 patients with a diagnosis of RLS. The mean age of the cohort was 62.9; 66.6% were women and 82.3% were white. The prevalence of any DA exposure was 40.3%. Compared to the reference group (no use and ≤1 year), the crude HRs for lung cancer were 1.16 (95% CI 0.99-1.36) and 1.14 (95% CI 0.86-1.51) for 1-3 years and >3 years of cumulative DA use, respectively. The adjusted HR for lung cancer was 1.05 (95% CI 0.88-1.25) for 1-3 years and 1.02 (95% CI 0.76-1.37) for >3 years of cumulative DA use, respectively. At typical doses for the clinical management of RLS, long-term DA use was not associated with risk of lung cancer.
Substances chimiques
Dopamine Agonists
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
726-734Subventions
Organisme : NIA NIH HHS
ID : K24 AG075234
Pays : United States
Organisme : NIH HHS
ID : T32GM-075766
Pays : United States
Organisme : NIH HHS
ID : T32GM-075766
Pays : United States
Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Barta JA, Powell CA, Wisninivesky JP. Global epidemiology of lung cancer. Ann Glob Health. 2019;85(1):8.
Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):1-61.
Lung. International Agency for Research on Cancer. World Health Organization. Accessed June 21, 2021. https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf
Wong MCS, Xiang Lao Q, Ho KF, Goggins WB, Tse SLA. Incidence and mortality of lung cancer: global trends and association with socioeconomic status. Sci Rep. 2017;7(1):14300.
Alberg AJ, Nonemaker J. Who is at risk for lung cancer? Population-level and individual-level perspectives. Semin Resp Crit Care Med. 2008;29(3):223-232.
Ramalingam S, Owonikoko T, Khuri F. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J Clin. 2011;61(2):91-112.
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung carcinoma. Nature. 2018;553:446-454.
Cancer Facts and Figures. American Cancer Society; 2018. Accessed November 15, 2020. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf
Lou Y, Dholaria B, Soyano A, et al. Survival trends among non-small-cell lung cancer patients over a decade: impact of initial therapy at academic centers. Cancer Med. 2018;7:4932-4942.
Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Eng J Med. 2008;359:1367-1380.
Comella C. Treatment of restless legs syndrome. Neurotherapeutics. 2014;11(1):177-187.
Fulda S, Wetter T. Dopamine agonists for the treatment of restless legs syndrome. Expert Opin Pharmacother. 2005;6(15):2655-2666.
Patel T, Chang F. Parkinson's disease guidelines for pharmacists. Can Pharm J. 2014;147(3):161-170.
Hoeppner LH, Wang Y, Sharma A, et al. Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells. Mol Oncol. 2015;9(1):270-281.
Senogles SE. D2 dopamine receptor-mediated antiproliferation in a small cell lung cancer cell line, NCI-H69. Anticancer Drugs. 2007;18:801-807.
Huang H, Wu K, Ma J, Du Y, Cao C, Nie Y. Dopamine D2 receptor suppresses gastric cancer cell invasion and migration via inhibition of EGFR/AKT/MMP-13 pathway. Int Immunopharmacol. 2016;39:113-120.
Chakroborty D, Sarkar C, Mitra RB, Banerjee S, Dasgupta PS, Basu S. Depleted dopamine in gastric cancer tissues. Dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin Cancer Res. 2004;10:4349-4356.
Sarkar C, Chakroborty D, Chowdury UR, Dasgupta PS, Basu S. Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clin Cancer Res. 2008;14(8):2502-2510.
Wang V, Chao TH, Hsieh CC, Lin CC, Kao CK. Cancer risks among the users of ergot-derived dopamine agonists for Parkinson's disease, a nationwide population-based survey. Parkinsonism Relat Disord. 2015;21:18-22.
Yamamoto H, Yatabe Y, Toyooka S. Inherited lung cancer syndromes targeting never smokers. Transl Lung Cancer Res. 2018;7(4):498-504.
Lin PY, Chang SN, Hsiao TH, Huang BT, Lin CH, Yang PC. Association between Parkinson's disease and risk of cancer in Taiwan. JAMA Oncol. 2015;1(15):633-640.
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-957.
Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial). J Clin Oncol. 2003;21(12):2237-2246.
Optum Clinformatics® Data Mart User Guide. Version7; 2017.
Bliwise DL, Zhang RH, Kutner NG. Medications associated with restless legs syndrome: a case-control study in the US Renal Data System (USRDS). Sleep Med. 2014;15(10):1241-1245.
Molnar MZ, Lu JL, Kalantar-Zadeh K, Kovesdy CP. Association of incident restless legs syndrome with outcomes in a large cohort of US veterans. J Sleep Res. 2016;25(1):47-56.
Freedman M, Wu J, Chen H, et al. Associations between cancer and Parkinsons' disease in US elderly adults. Int J Epidemiol. 2016;45:741-751.
Bajaj A, Driver JA, Schernhammer ES. Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control. 2010;21:697-707.
Xie X, Luo X, Xie M, Liu Y, Wu T. Risk of lung cancer in Parkinson's disease. Oncotarget. 2016;7(47):77319-77325.
Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007;16(3):241-249.
Khan N, Patel D, Trivedi C, et al. Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: a nationwide cohort study. Clin Gastroenterol Hepatol. 2018;16(12):1919-1927.e3.
Pottergard A, Friis S, Stürmer T, Jesper H, Bahmanyar S. Considerations for pharmacoepidemiological studies of drug-cancer associations. Basic Clin Pharmacol Toxicol. 2017;122:451-459.
Kutikova L, Bowman L, Chang S, Long SR, Obasaju C, Crown WH. The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer. 2005;50(2):143-154.
Murawski M, Walter J, Schwarzkopf L. Assessing the lung cancer comorbidome: an analysis of German claims data. Lung Cancer. 2019;127:122-129.
Torre LA, Siegel LR, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1-19.
Desai RJ, Solomon DH, Shadick N, et al. Identification of smoking using Medicare data - a validation study of claims-based algorithms. Pharmacoepidemiol Drug Saf. 2016;25:472-475.
Vanderbrouke J, Pearce N. Point: incident exposure, prevalent exposures and causal inference: does limiting studies to persons who are followed from first exposure onward damage epidemiology? Am J Epidemiol. 2015;182(10):826-833.
Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920.
Weissenrieder JS, Neighbors JD, Mailman RB, Hohl RJ. Cancer and the dopamine D2 receptor: a pharmacological perspective. J Pharmacol Exp Ther. 2019;370(1):111-126.
Wang X, Wang ZB, Luo C, et al. The prospective value of dopamine receptors on bio-behavior of tumor. J Cancer. 2019;10:1622-1632.
Collo G, Cavalleri L, Bono F, et al. Ropinirole and pramipexole promote structural plasticity in human iPSC-derived dopaminergic neurons via BDNF and mTOR signaling. Neural Plast. 2018;2018:4196961.
Choi J, Horner KA. Dopamine agonists. StatPearls. StatPearls Publishing; 2021.
Turner R, Chen YW, Fernandes AW. Validation of a case-finding algorithm for identifying patients with non-small cell lung cancer (NSCLC) in administrative claims bases. Front Pharmacol. 2017;8(883):1-8.
Ung MH, MacKenzie TA, Onega TL, Amos CI, Cheng C. Statins associated with improved mortality among patients with certain histological subtypes of lung cancer. Lung Cancer. 2018;126:89-96.
Wall RJ, Shyr Y, Smalley W. Nonsteroidal anti-inflammatory drugs and lung cancer risk: a population-based case control study. J Thorac Oncol. 2007;2(2):109-114.